STD Self-Diagnostics Market is segmented By Type (Chlamydia testing, Syphilis testing, Gonorrhea testing, Herpes Simplex Virus testing, Human Papilloma Virus testing, Human Immunodeficiency Virus testing, Chancroid testing, Others), By Location of Testing (Laboratory Testing, Point of Care (POC) testing), By Testing Devices (Laboratory Devices, Point of Care (POC) Devices), By Region (North America, Europe, South America, Asia-Pacific, Middle East, and Africa) – Share, Size, Outlook, and Opportunity Analysis, 2023-2030.
STD Self-Diagnostics Market
STD Self-Diagnostics Market is estimated to reach at a CAGR 6% during the forecast period (2023-2030). A bacterial or viral infection causes Sexually Transmitted Disease (STD) in the body.
More than 30 different infections are transmitted through the exchange of semen, blood, and other body fluids; or by direct contact with the affected body areas of people with STDs. STD self-diagnostics become a savior because it does not require any medical professional, anyone can do self-testing without any medical assistance within a few minutes.
STD Self-Diagnostics Market
|
Metrics |
Details |
|
Market CAGR |
6% |
|
Segments Covered |
By Type, By Location of Testing, By Location of Testing, By Testing Devices, and By Region |
|
Report Insights Covered |
Competitive Landscape Analysis, Company Profile Analysis, Market Size, Share, Growth, Demand, Recent Developments, Mergers and acquisitions, New Product Launches, Growth Strategies, Revenue Analysis, and Other key insights. |
|
Fastest Growing Region |
Asia Pacific |
|
Largest Market Share |
North America |
STD Self-Diagnostics Market Dynamics
The STD self-diagnostics market growth is driven by the increasing global incidence of various STIs, rise in sedentary lifestyle adoption levels, and rising awareness & patient education, increasing demand for rapid and accurate diagnostic tests and presence of favorable government initiatives for STD testing in developing countries such as Brazil, India, and China are further estimated to boost the market growth.
The increasing prevalence of the sexually transmitted diseases is expected to drive the growth in the forecast period
A bacterial or viral infection causes Sexually Transmitted Disease (STD) in the body. More than 30 different infections are transmitted through the exchange of semen, blood, and other body fluids; or by direct contact with the affected body areas of people with STDs. For instance, according to WHO 2019 report, more than 1 million Sexually Transmitted Infections (STIs) are acquired every day worldwide. Each year, there are an estimated 376 million new infections with 1 of 4 STIs.
Besides this, both developed and developing countries elevated their healthcare expenditure and spent on new technologies and Research and Development to increase the health quality of the population. According to WHO, US$ 8.3 trillion was spent on healthcare in 2020 globally. Therefore, all these factors can help grow STD self-diagnostics during the forecast period.
Growing government initiatives and national programs for sexually transmitted diseases is expected to drive growth in the forecast period
Government initiatives and national programs for sexually transmitted diseases drive demand for the growth of the market. For Instances, In January 2020, Central Disease control continued to support specialty clinics by scaling up HIV prevention services in STD with the help of Notice of Funding Opportunity (NOFO).
STD self-diagnostics become a savior because it does not require any medical professional; anyone can do self-testing without any medical assistance within few minutes. It is rapid, easily available, and affordable. Therefore, all these factors drive the STD self-diagnostics sales during the forecast period.
Lack of awareness about STD self-diagnostics may hamper the market growth
Lack of awareness about STD self-diagnostics in developing countries and limited access to STD diagnosis in developing regions is expected to restrain the market growth.
COVID-19 Impact on STD Self-Diagnostics Market
Following the COVID-19 outbreak in December 2019, the disease has spread to over 100 countries globally, and the World Health Organization has declared it a public health emergency. According to the World Health Organization’s report, the coronavirus (COVID-19) manifestation has resulted in more than 52.7 million infected individuals worldwide as of November 13, 2020.
COVID-19 has affected every market globally and has also impacted the global herpes simplex virus treatment market in the following ways; by directly affecting production and demand, creating disruptions in distribution channels, and its financial impact on firms and financial markets.
STD Self-Diagnostics Market Segment Analysis
The chlamydia testing segment is expected to hold largest share in this market segment
Chlamydia testing for sexually active women aged below 25 years is strictly recommended by the U.S Preventive Services Task Force (PSTF) owing to increasing prevalence of chlamydia infection globally. The prevalence of chlamydia was higher in women than in men. The prevalence for women varied from 1.1% to 10.6% and for men from 0.1% to 12.1%.
The laboratory testing devices segment is expected to hold largest share in this market segment
Laboratory testing devices segment dominated the market. Immunochromatographic assays were most preferred devices for STD diagnosis in laboratory testing devices segment. Increasing technological advancements are estimated to enhance usage rates of thermal cyclers over the forecast period. Factors such as faster diagnosis with POC tests and expected rise in adoption of POCs in future significantly contribute toward the growth of this segment.
The laboratory testing segment is expected to hold largest share in this market segment
Laboratory testing held the largest market share owing to the availability of cost-effective diagnostic tests used for multiple STIs at a single location such as public health labs.
STD Self-Diagnostics Market Geographical Share
North America region holds the largest market share of global STD self-diagnostics market
U.S. and Canada are the leading markets for STD self-diagnostics due to the region's high prevalence of the disease. According to Centres for Disease Control and Prevention (CDC) 2019 reported data, sexually transmitted is the most prevalent infectious disease 50-100 times higher than industrialized nations, about 85% in the U.S. One in four occurs in someone between the ages of 16 and 19.
About 12 million new STD infections occur in the United States each year. At the age of 25, more than 64% of people are affected by STD infections.
Also, the presence of key players, advancement and adoption of new technologies such as immunochromatographic device by Chembio Diagnostics Systems Inc played a vital role in increasing growth for the STD self-diagnostics in the region.
STD Self-Diagnostics Market Competitive Landscape
The global STD self-diagnostics market is moderately competitive with presence of global companies. Some of the key players which are contributing to the growth of the market include F. Hoffmann-La Roche, Abbott Laboratories, Becton Dickinson and Company, Danaher Corporation, Affymetrix, BioMerieux, Cepheid Inc., Alere Inc., DiaSorin, and Orasure. The major players are adopting several growth strategies such as product launches, acquisitions, and collaborations, which are contributing to the growth of the market globally. For instance, in march 2021, European Centre for Disease Prevention and Control initiated novel strategies and approaches (using existing and/or novel testing technologies) on access testing on key populations at-risk for sexually transmitted infections.
Key Companies to Watch
F. Hoffmann-La Roche
Overview: F. Hoffman-La Roche AG is a global pioneer in pharmaceuticals and diagnostics focused on advancing science to improve people’s lives. F. Hoffman-La Roche AG is also the world leader in in vitro diagnostics and tissue-based cancer diagnostics, and a frontrunner in diabetes management. The company also aims to improve patient access to medical innovations by working with all relevant stakeholders. Thirty medicines developed by Roche are included in the World Health Organization Model Lists of Essential Medicines, among them life-saving antibiotics, antimalarials and cancer medicines. Roche has been recognized as the Group Leader in sustainability within the Pharmaceuticals, Biotechnology & Life Sciences Industry ten years in a row by the Dow Jones Sustainability Indices (DJSI).
Product Portfolio: The company is the world’s largest biotech company, with truly differentiated medicines in oncology, immunology, infectious diseases, ophthalmology and diseases of the central nervous system.
Key Developments: In May 2020, F. Hoffmann-La Roche Ltd has acquired Stratos Genomics. This enhances the diagnosis segment of the company.